In glioblastoma, specific genetic and transcriptional subgroups might be differentially sensitive to the inhibition of NAMPT.7,8,64,225,306,307 IDH mutations sensitize CSCs of glioblastoma to NAMPT inhibition due to low levels of NAPRT1, resulting in low NAD levels. This evidence concerns the gene NAMPT and glioblastoma.